Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a biotechnology company focused on precision genetic medicine for rare diseases, with a stated leadership position in Duchenne muscular dystrophy and an expanding portfolio across muscle, central nervous system and cardiac conditions. The SRPT news feed on Stock Titan aggregates company-issued updates and market-moving announcements that reflect Sarepta’s scientific, regulatory and financial developments.
Investors and followers of SRPT can use this page to review earnings and revenue updates, such as preliminary net product revenue reports that break out contributions from ELEVIDYS and the company’s PMO franchise, as well as quarterly financial results and commentary on cash position and capital structure. News items also cover clinical and regulatory milestones, including updates to the ELEVIDYS prescribing information, FDA safety labeling decisions, and the design and progress of studies like ENDEAVOR and ESSENCE.
The feed highlights pipeline progress in Sarepta’s next-generation siRNA platform, including clinical trial applications and early-stage data for programs such as SRP-1003 for myotonic dystrophy type 1 and SRP-1005 for Huntington’s disease. It also captures disclosures about strategic restructuring, clinical holds in limb girdle muscular dystrophy gene therapy programs, and collaborations with partners like Arrowhead Pharmaceuticals.
Corporate and capital markets news—such as convertible note exchanges, private placements of common stock, inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor conference presentations—are also included. By reviewing this consolidated SRPT news stream, users can quickly see how Sarepta communicates its progress in genetic medicine, regulatory interactions, financing activities and strategic priorities over time.
Sarepta Therapeutics (NASDAQ:SRPT) will announce its second quarter 2021 financial results after market close on August 4, 2021. A conference call is scheduled for 4:30 p.m. E.T. to discuss these results and provide a corporate update. Investors can access the call via phone or through the company's website, which will also archive the event for 90 days. Sarepta is focused on developing precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy, with a robust pipeline of over 40 programs.
Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to two new employees as part of its compensation strategy. Approved on June 30, 2021, these awards include options to purchase 2,450 shares and 1,250 restricted stock units (RSUs). The options have an exercise price of $77.74 per share, equivalent to the closing price on the grant date. The vesting schedule includes a one-year cliff, with full vesting over four years, contingent on continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and highlights Sarepta's commitment to attracting top talent.
Sarepta Therapeutics (NASDAQ:SRPT) announced participation in two virtual investor conferences. The management will take part in:
- Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 1:20 p.m. E.T.
- BofA Securities 2021 Napa BioPharma Virtual Conference on June 16 at 10:30 a.m. E.T.
Both presentations will be webcast live on Sarepta's website and archived for 90 days. Sarepta focuses on precision genetic medicine and has over 40 programs targeting rare diseases, notably Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) announced on May 28, 2021, that it granted equity awards to six new employees as part of its 2014 Employment Commencement Incentive Plan. The awards include options to purchase 6,295 shares at an exercise price of $75.65 per share and a total of 2,950 restricted stock units (RSUs). The options will vest over four years, while the RSUs will also fully vest by the fourth anniversary of the grant date. This step aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing Sarepta's commitment to attracting talent in precision genetic medicine for rare diseases.
Sarepta Therapeutics (NASDAQ:SRPT) announced positive results from the first 11 participants in Study SRP-9001-103 ENDEAVOR. The study shows robust transduction with mean vector genome copies of 3.87 per nucleus and micro-dystrophin expression levels at 55.4% of normal. Proper localization of micro-dystrophin was confirmed, with 70.5% dystrophin-positive fibers. The safety profile remains consistent with previous studies, with no new safety signals. These findings support the potential of SRP-9001 as a transformative therapy for Duchenne muscular dystrophy, leading to plans for an FDA meeting to start a registrational study.
Sarepta Therapeutics (NASDAQ:SRPT) will host a conference call on May 18, 2021, at 8:30 am ET, to share results from the SRP-9001-103 clinical trial, also known as ENDEAVOR. This trial evaluates SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) for treating Duchenne muscular dystrophy. It marks the first use of commercially representative material in a clinical setting. The event will be webcast live and archived for a year.
Sarepta Therapeutics (NASDAQ:SRPT) reported first-quarter 2021 net product sales of $124.9 million, a 24% increase from the previous year. The company launched its third RNA therapy for Duchenne, AMONDYS 45™, shortly after FDA approval. Significant advancements in pipeline development were noted, particularly with SRP-5051, which showed an 18x increase in exon skipping compared to a standard treatment. However, the company reported a GAAP net loss of $167.3 million, reflecting increased R&D expenses of $195.1 million. Cash reserves decreased from $1.9 billion to $1.7 billion.
Sarepta Therapeutics (NASDAQ:SRPT) announced its participation in two upcoming virtual investor conferences. Management will engage in fireside chats at the BofA Securities Virtual Healthcare Conference on May 11, 2021, at 2:00 p.m. E.T., and the RBC 2021 Global Healthcare Conference on May 18, 2021, at 2:30 p.m. E.T. Both presentations will be webcast live and archived on Sarepta’s website for 90 days. Sarepta is dedicated to precision genetic medicine for rare diseases, holding a leadership position in Duchenne muscular dystrophy and limb-girdle muscular dystrophies.
Sarepta Therapeutics (NASDAQ:SRPT) announced positive results from the Phase 2 MOMENTUM study of its next-generation treatment, SRP-5051, for Duchenne muscular dystrophy. The 30 mg/kg dose revealed a mean exon skipping of 10.79% and dystrophin expression of 6.55% after 12 weeks, significantly outperforming the eteplirsen comparison group. The company anticipates achieving over 10% dystrophin levels with ongoing monthly dosing. Despite manageable hypomagnesemia in some patients, Sarepta is optimistic about advancing toward regulatory discussions for accelerated approval.
Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to four new employees on April 30, 2021, under its 2014 Employment Commencement Incentive Plan. The total awards included options for 8,615 shares and 3,275 restricted stock units (RSUs). The options have an exercise price of $70.84 per share, matching the closing stock price on the grant date. Vesting for options and RSUs is set over four years, contingent on continued employment.